Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06601517
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-03
Brief Title:
A Drug-Drug Interaction DDI Study of HDM1002 With Repaglinide Atorvastatin Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase I Open-Label Single-Arm Fixed-Sequence Study to Evaluate the Effect of Repeated Administration of HDM1002 on the Pharmacokinetics of Repaglinide Atorvastatin Digoxin and Rosuvastatin in Healthy and Overweight Adult Chinese Subjects
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide atorvastatin digoxin and rosuvastatin in healthy adult subjects The safety and tolerability of HDM1002 with repaglinide atorvastatin digoxin and rosuvastatin when given separately or together will also be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None